Additional details on the Senior Notes are available in the Company's Form 8-K, which has been filed with the Securities and Exchange Commission. Forward-Looking Statements This press release contains certain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements about the delisting of the Warrants from NYSE American, tradin ...

MINNEAPOLIS, MN, June 14, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO"), today announced it has entered into two share exchange agreements with Rennova Health, Inc., an OTC listed company ("Rennova") (OTC: RNVA). In the first agreement, equity in Myrtle Recovery Centers, Inc., Rennova's behavioral health services subsidiary, will be exchanged for $500,000 of common stock in FOXO, subject to adjustments. In the second agreement, equity in Rennova Community He ...

Foxo Technologies will acquire the shares of Myrtle Recovery Centers for $500,000. However, it will use shares of FOXO stock to acquire these shares instead of cash. FOXO Stock Movement Today Investors looking for more of the most recent stock market stories will want to stick around! On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39783 FOXO TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) | Delaware | 85-1050265 | | --- | --- | | (State or other jurisdiction of | (IRS Employer | | incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39783 FOXO TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 85-1050265 (State or other jurisdiction of incorporation or organization) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39783 FOXO TECHNOLOGIES INC. or (Exact name of registrant as specified in its charter) | Delaware | 85-105026 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39783 FOXO TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 85-1050265 ( ...

Financial Performance and Capital Requirements - The company has accumulated deficits of $147,231,000 and $51,976,000 as of December 31, 2022 and December 31, 2021, respectively, with net losses of $95,255,000 and $38,488,000 for the years ended December 31, 2022 and 2021[95]. - The company expects to require significant capital to commercialize its product and service offerings and grow its business, which may not be available on acceptable terms[100]. - The company has a history of losses and may not achieve or maintain profitability in the future, with expectations of increasing net losses in the near term due to ongoing investments[95]. - The company has significant operating costs expected to be incurred in the next twelve months, raising concerns about its ability to continue as a going concern[98]. - The company’s outstanding indebtedness includes restrictive covenants that could limit financial flexibility and impact its financial condition[120]. - The company acknowledges that changes in general economic conditions, such as interest rates, could adversely impact its operating results and capital raising ability[130]. Operational Risks and Management Changes - Recent management changes, including the departure of the CEO and COO, could disrupt operations and impair the ability to attract and retain key personnel[104]. - The company is transitioning from a research and development focus to supporting both R&D and commercial activities, facing risks and uncertainties typical of development-stage companies[118]. - The company may experience difficulties in maintaining relationships with key distributors, which could adversely affect its ability to sell products and generate revenue[179]. Market Competition and Product Development - The company intends to provide consumer engagement through its health and wellness platform, but faces increasing competition in the personal health and wellness testing market[92]. - The company faces substantial competition from larger, established companies in the life insurance industry, which may impair its ability to commercialize its products and services[159]. - The company may not be able to develop epigenetic biomarkers that attract and retain life insurance carriers as customers, which is critical for its success[92]. - The company has developed ancillary products and services, such as the "MethylSuite" software, but these are not expected to generate significant revenue[173]. - The company anticipates competition based on product efficacy, accuracy, availability, and price, which will impact its competitive position[161]. Regulatory and Compliance Challenges - The company may be subject to laws and regulations relating to laboratory testing, which could materially adversely impact its ability to offer products or services[92]. - The company faces significant regulatory compliance obligations under GDPR and UK GDPR, which could impose fines of up to 4% of global annual turnover or €20 million for serious violations[140]. - The company is subject to various data privacy laws, including the California Consumer Privacy Act (CCPA), which imposes fines of up to $7,500 per violation, potentially increasing compliance costs[186]. - Noncompliance with the General Data Protection Regulation (GDPR) could result in fines of up to €20 million or 4% of global annual revenues, impacting the company's financial condition[187]. - The company’s underwriting technology and services may be subject to FDA regulations, which could adversely affect operations if premarket review or approval is required[170]. Intellectual Property and Legal Risks - The company relies on proprietary technology and intellectual property for its business success, with a focus on protecting trade secrets related to machine learning models[194]. - The uncertainty surrounding patent and trademark prosecution in biotechnology could affect the company's ability to secure and enforce intellectual property rights[196]. - The company may face claims regarding the inventorship or ownership of its patents, which could lead to costly litigation and loss of valuable intellectual property rights[206]. - The company anticipates increased litigation related to intellectual property as the industry expands, which could divert resources and management attention[209]. - The company’s proprietary information is at risk of misappropriation, which could materially impact its competitive advantages[213]. Customer Engagement and Data Security - Security incidents or errors in systems could lead to loss of customer information and damage to the company's reputation, impacting business operations[127]. - The company is at risk of reputational harm if it fails to address customer concerns regarding privacy and security, which could affect customer retention and acquisition[131]. - The company may face reputational damage and financial harm due to potential security breaches or unauthorized disclosures of customer data[184]. Stock Performance and Market Conditions - The Class A Common Stock has traded as low as $0.23 per share since the Business Combination, indicating significant volatility in the market[219]. - The company is subject to continued listing standards of the NYSE American, which includes maintaining a minimum stock price of $0.20 per share[220]. - The company’s stock price may be adversely affected by negative perceptions from securities analysts or investors during intellectual property litigation[214].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Securities registered pursuant to Section 12(b) of the Act: | Title of Each Class: | Trading Symbol(s) | Name of Each Exchange on Which Registered: | | --- | --- | --- | | Class A Common Stock, par value $0.0001 | FOXO | NYSE American | | Warrant, each whole warrant exercisable ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39783 DELWINDS INSURANCE ACQUISITION CORP. | (Exact name of registrant as specified in its charter) | | | ...